Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Sun Pharmaceutical Industries, Inc.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients must have 4 to 8 clinically diagnosed, non-hyperkeratotic, non-hypertrophic AK lesions within a 25 cm2 contiguous treatment area on either the face or balding scalp
Women either must be 1 year post-menopausal, surgically sterile, or agree to use a medically accepted form or birth control
Free of any systemic or dermatological disorder
Any skin type or race, providing the skin pigmentation will allow discernment of erythema
You may not be if
Basal cell or squamous cell carcinoma, or other possible confounding skin conditions (on face and scalp)
History of cutaneous hyperreactivity or facial irritation to topical products
Engaging in activities involving excessive or prolonged exposure to sunlight
Receiving systemic cancer chemotherapy, psoralen plus UVA therapy, UVB therapy, laser abrasion, dermabrasion, glycolic acids, or chemical peels 6 months prior to study entry
Currently using or have used systemic steroids 2 months prior to study
Currently using or have used on the treatment area over-the-counter retinol products, corticosteroids, cryosurgery, curettage, 5-fluorouracil, or other topical actinic keratosis treatments 28 days prior to randomization
Pregnant or nursing mothers
History of allergy or sensitivity to imiquimod or related compounds or other components of the formulation
Taking immunosuppressant medication
Clareo Health | Bioequivalence Study of Two Imiquimod Cream 5%
